GT Biopharma Inc. Common Stock (GTBP)
Stock · NASDAQ · Health Care
$7.03as of 10/16/2026
Price chart
Active signals
GTBP Signal Track Record
How signals performed across all stocks →What GTBP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 28 | -8.7% | 39% | September 3, 2026 |
| Volume Spike | 28 | -5.9% | 39% | September 3, 2026 |
| Bollinger Band Breakout | 20 | -17.2% | 30% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -18.2% | 25% | May 1, 2025 |
| Any 20-session window (baseline) | -8.6% | 30% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1
- Website
- www.gtbiopharma.com/
Fundamentals
- 1-day range
- $8.65$11.98
- Market cap
- $13.35M
- P/E (trailing)
- —
- P/E (forward)
- -1.08
- EPS (trailing)
- $-47.51
- Dividend yield
- —
- Beta
- 0.82
- Avg. volume
- 51.8K
- Dividend pay date
- August 21, 2017
How GT Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2015 annual results
Source: 10-K filed Mar 30, 2016 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
GT Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GTBPGT Biopharma Inc. Common Stock$7.03▼ 4.48%Market cap $13.35MP/E —$4.91$34.25
- PBMPsyence Biomedical Ltd. Common Shares$4.22▼ 2.31%Market cap $13.31MP/E —$1.92$143.5
- CMMBChemomab Therapeutics Ltd. American Depositary Share$1.26▼ 1.94%Market cap $12.95MP/E —$1.05$3.5
- AEONAEON Biopharma Inc. Class A Common Stock$0.232▼ 4.53%Market cap $13.80MP/E —$0.1772$1.45
- PTNPalatin Technologies Inc. Common Stock$6.02▼ 7.24%Market cap $14.00MP/E 92.55$5.61$31
- VTGNVistagen Therapeutics Inc. Common Stock$0.2▼ 4.76%Market cap $12.59MP/E —$0.198$5.14
- AKTXAkari Therapeutics plc ADS$8.18▼ 7.47%Market cap $14.14MP/E Infinity$3.02$39.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GTBP GT Biopharma Inc. Common Stock | $13.35M | — | $7.03 | ▼ 4.48% | $4.91$34.25 |
| PBM Psyence Biomedical Ltd. Common Shares | $13.31M | — | $4.22 | ▼ 2.31% | $1.92$143.5 |
| CMMB Chemomab Therapeutics Ltd. American Depositary Share | $12.95M | — | $1.26 | ▼ 1.94% | $1.05$3.5 |
| AEON AEON Biopharma Inc. Class A Common Stock | $13.80M | — | $0.232 | ▼ 4.53% | $0.1772$1.45 |
| PTN Palatin Technologies Inc. Common Stock | $14.00M | 92.55 | $6.02 | ▼ 7.24% | $5.61$31 |
| VTGN Vistagen Therapeutics Inc. Common Stock | $12.59M | — | $0.2 | ▼ 4.76% | $0.198$5.14 |
| AKTX Akari Therapeutics plc ADS | $14.14M | Infinity | $8.18 | ▼ 7.47% | $3.02$39.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 1.37M
- Total value held
- $538.1K
- Institutional holders
- 39
- Unknown451.9K
- Unknown294.5K
- Unknown93.6K
- Unknown66.2K
- Unknown50.0K
- Unknown46.0K
- Unknown31.8K
- Unknown30.4K
- Unknown23.4K
- Unknown21.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
GT Biopharma Files Prospectus for Up to 13.5M Shares
GT Biopharma Inc. has filed a prospectus that allows up to 13,502,835 shares of its common stock to be sold by existing shareholders. This filing gives the company and its investors a formal framework for a potential share sale. The prospectus does not change the company’s current operations or financial outlook. Investors can review the details to understand how the sale could affect share supply.
GT Biopharma Files Prospectus for Up to 13.5M Shares. GT Biopharma Inc. has filed a prospectus that allows up to 13,502,835 shares of its common stock to be sold by existing shareholders. This filing gives the company and its investors a formal framework for a potential share sale. The prospectus does not change the company’s current operations or financial outlook. Investors can review the details to understand how the sale could affect share supply.